Castle Biosciences, Inc. (CSTL)
CSTL Stock Price Chart
Explore Castle Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze CSTL price movements and trends.
CSTL Company Profile
Discover essential business fundamentals and corporate details for Castle Biosciences, Inc. (CSTL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
25 Jul 2019
Employees
784.00
Website
https://castlebiosciences.comCEO
Derek J. Maetzold
Description
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CSTL Financial Timeline
Browse a chronological timeline of Castle Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.44, while revenue estimate is $86.24m.
Earnings released on 6 May 2026
EPS came in at -$0.49 matching the estimated -$0.49, while revenue for the quarter reached $84.23m , beating expectations by +6.31%.
Earnings released on 26 Feb 2026
EPS came in at -$0.08 surpassing the estimated -$0.23 by +65.22%, while revenue for the quarter reached $87.01m , beating expectations by +8.91%.
Earnings released on 3 Nov 2025
EPS came in at -$0.02 surpassing the estimated -$0.34 by +94.12%, while revenue for the quarter reached $83.04m , beating expectations by +3.31%.
Earnings released on 4 Aug 2025
EPS came in at $0.15 surpassing the estimated -$0.51 by +129.41%, while revenue for the quarter reached $86.19m , beating expectations by +26.75%.
Earnings released on 5 May 2025
EPS came in at -$0.20 falling short of the estimated -$0.08 by -150.00%, while revenue for the quarter reached $87.99m , beating expectations by +22.51%.
Earnings released on 27 Feb 2025
EPS came in at $0.32 surpassing the estimated -$0.04 by +900.00%, while revenue for the quarter reached $86.31m , beating expectations by +2.89%.
Earnings released on 4 Nov 2024
EPS came in at $0.08 surpassing the estimated -$0.06 by +233.33%, while revenue for the quarter reached $85.78m , beating expectations by +6.46%.
Earnings released on 5 Aug 2024
EPS came in at $0.31 surpassing the estimated -$0.27 by +214.81%, while revenue for the quarter reached $87.00m , beating expectations by +25.47%.
Earnings released on 2 May 2024
EPS came in at -$0.09 surpassing the estimated -$0.37 by +75.68%, while revenue for the quarter reached $72.97m , beating expectations by +10.23%.
Earnings released on 28 Feb 2024
EPS came in at -$0.10 surpassing the estimated -$0.84 by +88.10%, while revenue for the quarter reached $66.12m , beating expectations by +17.48%.
Earnings released on 2 Nov 2023
EPS came in at -$0.26 surpassing the estimated -$0.92 by +71.74%, while revenue for the quarter reached $61.49m , beating expectations by +21.34%.
Earnings released on 2 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$1.01 by +30.69%, while revenue for the quarter reached $50.14m , beating expectations by +13.46%.
Earnings released on 3 May 2023
EPS came in at -$1.10 falling short of the estimated -$0.80 by -37.50%, while revenue for the quarter reached $42.04m , missing expectations by -1.16%.
Earnings released on 28 Feb 2023
EPS came in at -$0.78 surpassing the estimated -$0.91 by +14.29%, while revenue for the quarter reached $38.34m , beating expectations by +3.29%.
Earnings released on 2 Nov 2022
EPS came in at -$0.77 falling short of the estimated -$0.70 by -10.00%, while revenue for the quarter reached $37.01m , beating expectations by +6.49%.
Earnings released on 8 Aug 2022
EPS came in at -$0.06 surpassing the estimated -$0.58 by +89.66%, while revenue for the quarter reached $34.84m , beating expectations by +22.80%.
Earnings released on 9 May 2022
EPS came in at -$0.80 falling short of the estimated -$0.67 by -19.40%, while revenue for the quarter reached $26.85m , beating expectations by +6.42%.
Earnings released on 28 Feb 2022
EPS came in at -$0.25 surpassing the estimated -$0.43 by +41.86%, while revenue for the quarter reached $25.04m , beating expectations by +5.48%.
Earnings released on 8 Nov 2021
EPS came in at -$0.47 falling short of the estimated -$0.35 by -34.29%, while revenue for the quarter reached $23.48m , missing expectations by -0.74%.
Earnings released on 9 Aug 2021
EPS came in at -$0.34 falling short of the estimated -$0.29 by -17.24%, while revenue for the quarter reached $22.76m , beating expectations by +20.29%.
CSTL Stock Performance
Access detailed CSTL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
